Pharmafile Logo
Pharmafocus logo
Advanced Search

Zejula

Showing 4 posts of 4 posts found.

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023
Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …

News
gsk_boronia_australia

GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …

News
tesaro

New PARP inhibitor hits UK market, offering distinct advantage

December 18, 2017
Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …

News
88

Tesaro secures EU approval in specific ovarian cancer population

November 23, 2017
Sales and Marketing Europe, European Commission, Tesaro, Zejula, pharma

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.  Zejula is a poly (ADP-ribose) …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026